Topics:

International Survey Seeks Treatment Insights for Cancer Patients at Risk of Fatal Thromboembolism

International Survey Seeks Treatment Insights for Cancer Patients at Risk of Fatal Thromboembolism

Cancer patients are at high risk of potentially fatal blood clots that form in the large veins in the leg (venous thromboembolism) that, if unrecognized or untreated, can lead to a potentially fatal pulmonary embolism. In fact, as many as 1 in 7 hospitalized cancer patients die of a fatal thromboembolic event rather than their cancer.

A recently launched international initiative—Fundamental Research in ONcology and Thrombosis (FRONTLINE)—will be the first global survey to collect information from physicians treating cancer patients with the goal of establishing the risk of venous thrombosis, documenting the prevention and treatment strategies currently employed, and seeking national treatment variations.

Cancer specialists across Europe, North and South America and the Asia-Pacific region are expected to participate in FRONTLINE, and intensive efforts will be made to collect data from as large and representative a sample as possible. Importantly, participation will be encouraged from all types of medical centers, not only those that regularly take part in clinical trials. The results will help to build a picture of what is happening in routine clinical practice.

The FRONTLINE Survey will collect information on:

  • The types of cancer patients who develop venous thromboembolism, and with which cancer treatments

  • Strategies physicians use for prophylaxis, its diagnosis and treatment

  • Factors that may influence treatment decisions.

It is hoped that the FRONTLINE Survey may pave the way for an international registry of cases of cancer-associated thromboembolic disease.

Current Perceptions and Practice

Venous thrombosis is an important cause of morbidity and mortality in cancer patients, and yet the clinical impact is often underestimated. Little is known about prevention strategies, diagnosis, and treatment in routine clinical practice. FRONTLINE is designed to help researchers understand current practice patterns and key issues surrounding this important clinical problem. It is hoped that as many clinicians treating cancer as possible will contribute, thus helping to provide much new information on current perceptions and practice.

Led by a distinguished scientific steering committee chaired by Dr. Ajay Kakkar, of Hammersmith Hospital, Imperial College, London, the FRONTLINE Survey is supported by an unrestricted educational grant from the Pharmacia Corporation. For more information about FRONTLINE, visit www.frontlinesurvey.net, or contact:

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.